Table 2. Response to treatment of 5 patients with NP-C and Crohn’s-like disease.
| Patient ID | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EEN | Steroids,
systemic |
Steroids,
local |
5-ASA | IFX | ADA | Vedo | MTX | AZA / 6-MP | AB | Other | Side effects | |
| 1 | - | I, partial | - | I, poor | I, complete, M, partial,
loss of response after 2.5 years |
M, partial | - | - | - | - | - | |
| 2 | I, poor | I, partial | - | - | M, partial | - | - | - | M, partial | M, partial | - | - |
| 3 | - | I, partial | - | I, poor | M, partial | - | - | - | M partial | M, partial | Ustekinumab (M, partial). | - |
| 4 | - | I, partial | I, poor | - | M, partial | M, partial | M partial | M, partial | - | - | 2- hydroxypropyl-β-cyclodextrin | - |
EEN = exclusive enteral nutrition, IFX = infliximab, ADA = adalimumab MTX = methotrexate, AZA = azathioprine, 6-MP = 6 mercaptopurine, AB = antibiotics. I= induction, M = maintenance therapy. Response classified as complete, partial or poor. Complete induction was defined as successful induction of remission, partial as improvement of disease activity and poor as little or no response. Maintenance treatment was classified complete if there was control of intestinal inflammation with no flares or complications, partial if there was good control of IBD activity and poor if there was little or no response.